Top 10 Clinical Research Developments in Antiphospholipid Syndrome

Barbhaiya, Medha; Erkan, Doruk

doi:10.1007/s11926-013-0367-6

Cited by 4 publications

(1 citation statement)

References 82 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These autoimmune disorders may probably be related to each other in one way or the other, for example, due to the presence of aPL antibodies. 14 Patients suffering from these disorders are more at risk of suffering from an accelerated rate of progressive atherosclerosis which can finally result in ACS. 15 However, the impact of APS and/or SLE on the adverse cardiovascular outcomes in patients after PCI is still controversial.…”

Section: Discussionmentioning

confidence: 99%

Impact of Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus on the Long-term Adverse Cardiovascular Outcomes in Patients After Percutaneous Coronary Intervention

Bundhun

Boodhoo

Long³

et al. 2016

Medicine

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are 2 rare autoimmune disorders which commonly affect women. Several previous studies showed APS to have been evolved from SLE. Secondary APS often coexists with SLE. One common feature relating these 2 diseases are the antiphospholipid antibodies, which are found in most of the patients with APS and in approximately 30% to 40% of patients with SLE, among which, about 10% develop APS. The leading cause of death in these patients is from cardiovascular disease due to accelerated atherosclerosis, which often progresses more rapidly, compared with the general population. However, the impact of APS and/or SLE on the cardiovascular outcomes in patients undergoing percutaneous coronary intervention (PCI) is controversial. Therefore, to solve this issue, we aim to compare the long-term (≥1 year) adverse cardiovascular outcomes after PCI, in patients with APS and/or SLE, and those without these disorders.Medline and EMBASE databases were searched for studies comparing the long-term adverse cardiovascular outcomes between SLE and non-SLE, APS and non-APS, or SLE + APS and non-SLE + non-APS after PCI. We calculated odd ratios (OR) and 95% confidence intervals (CIs) for these categorical variables, and the pooled analyses were performed with RevMan 5.3.Seven studies consisting of a total of 253,436 patients (568 patients in the experimental group and 252,868 patients in the control group) were included in this meta-analysis. During a follow-up period of ≥1 year, mortality and myocardial Infarction (MI) were significantly higher in the experimental group (OR 2.02, 95% CI 1.63–2.49, P < 0.00001 and OR 1.59, 95% CI 1.23–2.05, P = 0.0004, respectively). Major adverse cardiac events and repeated revascularization were also significantly higher in the SLE/APS group (OR 2.40, 95% CI 1.42–4.03, P = 0.001 and OR 2.59, 95% CI 1.26–5.31, P = 0.01, respectively).Antiphospholipid syndrome and SLE are associated with significantly higher long-term (≥1 year) adverse cardiovascular outcomes after PCI. However, because of the limited number of patients and researches done, and due to a larger percentage of heterogeneity observed among several subgroups, this analysis may not generate a powerful result.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus on the Long-term Adverse Cardiovascular Outcomes in Patients After Percutaneous Coronary Intervention

Bundhun

Boodhoo

Long³

et al. 2016

Medicine

View full text Add to dashboard Cite

show abstract

Neonatal Antiphospholipid Syndrome

2014

View full text Add to dashboard Cite

Antiphospholipid antibody syndrome (APS) during pregnancy may result in pregnancy morbidity and passive transfer of antibodies to the fetus, resulting in an increased risk of prematurity, intrauterine growth restriction, thrombocytopenia, and developmental delay. Antiphospholipid antibodies may have an impact on neurodevelopment during fetal life. Although rare, persistence of these antibodies in the neonate may lead to thromboembolism, particularly if there is a concurrent infection and/or inherited thrombophilic disorders. Affected pregnant women need to be identified early during gestation so that they can have close monitoring of the placental circulation, fetal growth and development, and testing of serum antiphospholipid antibody levels. Neonates born to mothers with antiphospholipid antibody syndrome should have close neurodevelopment follow-up.

show abstract

Anticardiolipin and Anti-(32 Glycoprotein I Antibodies in Pregnant Women with Severe Pre-Eclampsia

Thabet¹,

AL-NASHAR²,

EL-KADR

2018

The Medical Journal of Cairo University

View full text Add to dashboard Cite

Background: APA have been associated with a number of obstetric complications however their role in the pathogenesis of preeclampsia has remained an issue of controversy.Aim of the Study: 1-Detection of Anticardiolipin antibodies and Anti-(3 2 glycoprotein I antibodies in pregnant women with severe pre-eclampsia. 2-Estimation of the prevalence of APA in pregnant women with severe pre-eclampsia. Patients and Methods:This is a case control study. Eighty pregnant women diagnosed of severe pre-eclampsia and twenty age-parity matched normal on-going pregnant women were recruited as participants for the study. Antiphospholipid antibodies were assayed using Dilute Russel Viper's Venom (DRVV) Lupus Anticoagulant (LA screen and confirm kits), Anticardiolipin Antibody (ACA) Enzyme Linked Immunosorbent Assay (ELISA) kits and Anti-(3 2 glycoprotein I antibodies ELISA-based test system were used. Results:The prevalence of APLA in severe pre-eclampsia was 6.25%, while none (0%) of the controls was positive.Conclusion: This study using DRVVT lupus anticoagulant, Anticardiolipin and Anti-(3 2 glycoprotein I assays has found the prevalence of APA in severe pre-eclampsia women seen at Women's Health Hospital, Assiut University to be 6.25%, while none (0%) of the controls was positive. These findings suggested that there is a relation between presence of APA and development of severe pre-eclampsia.

show abstract

Top 10 Clinical Research Developments in Antiphospholipid Syndrome

Cited by 4 publications

References 82 publications

Impact of Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus on the Long-term Adverse Cardiovascular Outcomes in Patients After Percutaneous Coronary Intervention

Impact of Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus on the Long-term Adverse Cardiovascular Outcomes in Patients After Percutaneous Coronary Intervention

Neonatal Antiphospholipid Syndrome

Anticardiolipin and Anti-(32 Glycoprotein I Antibodies in Pregnant Women with Severe Pre-Eclampsia

Contact Info

Product

Resources

About